Janssen-Cilag Ltd

50 - 100 Holmers Farm Way, High Wycombe, Bucks, HP12 4EG
Telephone: +44 (0)1494 567 567
Fax: +44 (0)1494 567 568
WWW: http://www.janssen.co.uk
WWW: http://www.janssen-medinfo.co.uk
Medical Information Direct Line: +44 (0)800 731 8450
Medical Information e-mail: medinfo@janssen-cilag.co.uk
Customer Care direct line: +44 (0)800 731 5550

Patient Information Leaflet last updated on the eMC: 07/11/2011
PIL RISPERDAL CONSTA 25, 37.5 and 50 mg powder and solvent for prolonged-release suspension for intramuscular injection

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 07/11/2011 and displayed until Current
Reasons for adding or updating:
  • Change/addition of instructions for reconstitution and/ or administration
  • Change to Further Information section
Updated on 07/04/2011 and displayed until 07/11/2011
Reasons for adding or updating:
  • Change to Further Information section
  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change to side-effects
Updated on 25/10/2010 and displayed until 07/04/2011
Reasons for adding or updating:
  • Change to date of revision
  • Change due to user-testing of patient information
Updated on 28/06/2010 and displayed until 25/10/2010
Reasons for adding or updating:
  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to dosage and administration
Updated on 18/01/2010 and displayed until 28/06/2010
Reasons for adding or updating:
  • Change/addition of instructions for reconstitution and/ or administration
  • Change to packaging
  • Change to date of revision
  • Change to dosage and administration
Updated on 01/05/2009 and displayed until 18/01/2010
Reasons for adding or updating:
  • Change to date of revision
  • Change to side-effects
Updated on 10/12/2008 and displayed until 01/05/2009
Reasons for adding or updating:
  • Change to date of revision
  • Change to, or new, use for medicine
  • Change to warnings or special precautions for use
  • Change to side-effects
Updated on 02/09/2008 and displayed until 10/12/2008
Reasons for adding or updating:
  • Change to MA holder contact details
Updated on 27/05/2008 and displayed until 02/09/2008
Reasons for adding or updating:
  • Improved Electronic Presentation
  • Change due to user-testing of patient information
Updated on 27/11/2007 and displayed until 27/05/2008
Reasons for adding or updating:
  • Change to side-effects
Updated on 01/11/2007 and displayed until 27/11/2007
Reasons for adding or updating:
  • Change to how to administer the medicine
Updated on 27/07/2007 and displayed until 01/11/2007
Reasons for adding or updating:
  • Change to side-effects
Updated on 27/09/2006 and displayed until 27/07/2007
Reasons for adding or updating:
  • Change to side-effects
Updated on 14/03/2006 and displayed until 27/09/2006
Reasons for adding or updating:
  • Change to warnings or special precautions for use
Updated on 03/03/2006 and displayed until 14/03/2006
Reasons for adding or updating:
  • Change to how to administer the medicine
Updated on 05/04/2005 and displayed until 03/03/2006
Reasons for adding or updating:
  • Change of contra-indications
  • Change to date of revision
  • Change to warnings or special precautions for use
Updated on 08/11/2004 and displayed until 05/04/2005
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 03/09/2004 and displayed until 08/11/2004
Reasons for adding or updating:
  • Change of licence holder
Updated on 19/12/2002 and displayed until 03/09/2004
Reasons for adding or updating:
  • Update to PIL
Updated on 13/08/2002 and displayed until 19/12/2002
Reasons for adding or updating:
  • New PIL for new product
Updated on 13/08/2002 and displayed until 13/08/2002
Reasons for adding or updating:
  • New PIL for new product

Active Ingredients/Generics

 
   risperidone